Live tape
Top 8, mentions 7d2,137GOOGL453 mentions▲ +0.06NVDA345 mentions▲ +0.07META271 mentions▲ +0.05QQQ266 mentions▲ +0.09SPY256 mentions▲ +0.04AAPL193 mentions▲ +0.04MSFT178 mentions▲ +0.06TSLA175 mentions▲ +0.06

Equity · Healthcare

MGX

Metagenomi Therapeutics, Inc. · NasdaqGS

$1.18 +1.29% 1D Finazon · prior-day close · Sep 14, 2026
Price · Chart
Our own end-of-day closes 59 sessions
$1.35 $1.15 22 Jun 14 Sep

The line runs $1.20 on 22 June through $1.18 on 14 September, on a scale from $1.15 to $1.35. Days the market did not trade hold the previous close, flat.

The chart above plots the price of MGX over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 59 sessions over that window: $1.20 on 22 June 2026 through $1.18 on 14 September 2026.

Market cap $44.4M
52-week range $1.14 – $3.37
Avg volume 4.2K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 20, 2026

MGX insider trades

SEC Form 4

MGX has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 5 December 2025.

Date Insider Type Shares Value
05 Dec 2025 Irish Jian Chief Executive Officer Sell 1,602 $3K
05 Dec 2025 Wapnick Pamela Chief Financial Officer Sell 1,576 $3K
05 Dec 2025 Wein Matthew See Remarks Sell 199 $0K
05 Dec 2025 Thomas Brian C. Sell 3,830 $7K
05 Sep 2025 Wein Matthew See Remarks Sell 199 $0K
05 Sep 2025 Irish Jian Chief Executive Officer Sell 1,602 $3K
05 Sep 2025 Wapnick Pamela Chief Financial Officer Sell 1,576 $3K
05 Sep 2025 Thomas Brian C. Sell 2,701 $5K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
01 Dec 2025 Wapnick Pamela Chief Financial Officer Award 120,000 $192K
01 Dec 2025 Wein Matthew See Remarks Award 96,000 $154K
01 Dec 2025 Irish Jian Chief Executive Officer Award 473,500 $398K
02 Sep 2025 Reid Laurence Award 42,000

MGX reported financials

SEC EDGAR XBRL

MGX reported revenue of $25.2M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$87.9M.

Figure Reported Period
Revenue $25.2M 31 Dec 2025 fiscal year
Net income −$87.9M 31 Dec 2025 fiscal year
Diluted EPS −$2.36 31 Dec 2025 fiscal year
Total assets $173.7M 30 Jun 2026 at period end
Total equity $112.6M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

MGX earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-0.73
31 Mar 2026 Q1 2026 $-0.61 $1M
31 Dec 2025 FY 2025 $-2.36 $25M
30 Sep 2025 Q3 2025 $-0.55 $9M
30 Jun 2025 Q2 2025 $-0.54 $9M
31 Mar 2025 Q1 2025 $-0.68 $4M
31 Dec 2024 FY 2024 $-2.36 $52M
30 Sep 2024 Q3 2024 $-0.51 $12M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

MGX institutional holders

SEC Form 13F

5 of the 45 institutional funds we track reported a MGX position for the quarter ended 30 Jun 2026 — a combined $1.8M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Renaissance Technologies Held (±25%) −5.8% shares 742,400 $883K
Two Sigma Investments Held (±25%) +3.4% shares 513,701 $611K
Millennium Management Trimmed −33.0% shares 114,025 $136K
Man Group Added +38.8% shares 109,130 $130K
Citadel Advisors Held (±25%) +5.0% shares 17,851 $21K
Marshall Wace Exited

Source: SEC EDGAR 13F filings

MGX fails-to-deliver

SEC CNS data

On 28 Aug 2026, 9,107 shares of MGX failed to deliver (about $11K) — the latest of 2 consecutive trading days with recorded fails.

Settlement date Shares failed Notional % of shares out
28 Aug 2026 9,107 $11K 0.024%
27 Aug 2026 3,636 $4K 0.010%
24 Aug 2026 14,539 $18K 0.038%
21 Aug 2026 22,151 $27K 0.059%
13 Aug 2026 6,741 $8K 0.018%
06 Aug 2026 1,901 $2K 0.005%

Source: SEC fails-to-deliver (CNS) data